Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children
Sponsor: Sohag University
Summary
About 40% of children with generalized convulsive status epilepticus (GCSE) are not terminated by first-line benzodiazepines (BDZs), and approximately 50% of BDZ-refractory GCSE are not controlled by second-line antiseizure medications. This study investigates the efficacy of ketamine-levetiracetam combination vs. levetiracetam alone for treating children with BDZ-refractory GCSE.
Official title: Efficacy of Combined Ketamine and Levetiracetam as a Second-line Anti-seizure Medication for Generalized Convulsive Status Epilepticus in Children
Key Details
Gender
All
Age Range
1 Year - 16 Years
Study Type
INTERVENTIONAL
Enrollment
124
Start Date
2025-07-02
Completion Date
2026-07-01
Last Updated
2025-07-03
Healthy Volunteers
No
Interventions
Ketamine
Intravenous ketamine (5 mg/ml concentration) 2 mg/kg (max 90 mg) over 2 minutes
Levetiracetam
Intravenous levetiracetam (50 mg/ml concentration) 60 mg/kg (max 4500 mg) over 5 minutes
Placebo
Intravenous isotonic saline 0.4 mL/kg (maximum 18 mL) over 2 minutes
Locations (1)
Department of Pediatrics at Sohag University Hospital
Sohag, Egypt